Go Pro
Eva Fortea-Verdejo

Eva Fortea-Verdejo Analyst Performance

Biotech equity research analyst at Wells Fargo & Company

Eva Fortea-Verdejo is a stock analyst at Wells Fargo & Company in the healthcare sector, covering 2 publicly traded companies. While full access to Eva Fortea-Verdejo's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Eva Fortea-Verdejo's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
2 Last 1 Years
Buy Recommendations
100.00% 2 Buy Ratings
Companies Covered
2 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy100.0%2 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

the majority (100.0%) have been Buy recommendations.

Exchange Coverage

ExchangePercentageCount
NASDAQ
50.0% of companies on NASDAQ
1 company
NYSE
50.0% of companies on NYSE
1 company

Eva Fortea-Verdejo, an analyst at Wells Fargo & Company, currently covers 2 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
2 companies
100.0%

Eva Fortea-Verdejo of Wells Fargo & Company specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
2 companies
100.0%

Eva Fortea-Verdejo's Ratings History at Wells Fargo & Company

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Xencor, Inc. stock logo
XNCR
Xencor
8/7/2025Lower Price Target$7.19$27.00Overweight
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
8/7/2025Lower Price Target$9.35$25.00Overweight